Clinical Trials Browser

INDUSTRY × rucaparib × Clear all

NCT03899155 2026-04-01

Pan Tumor Rollover Study

Phase 2 Recruiting

Neoplasms

NCT03768063 2026-01-29

IMbrella B

Phase 3 Active not recruiting

Neoplasms

NCT03338790 2026-01-27

CheckMate 9KD

Phase 2 Completed

292 enrolled 21 charts

Prostatic Neoplasms

NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Phase 1/2 Terminated

137 enrolled 31 charts

BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT02975934 2025-07-25

TRITON3

Phase 3 Completed

405 enrolled 34 charts 3 FDA

Metastatic Castration Resistant Prostate Cancer

NCT03522246 2025-06-24

ATHENA

Phase 3 Active not recruiting

1,097 enrolled 26 charts

Carcinoma, Ovarian Epithelial, Pathologic Complete Response, Fallopian Tube Neoplasms, Neoplasms

NCT04676334 2024-05-07

CATCH-R

Phase 3 Completed

34 enrolled 9 charts

GenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Genital Neoplasms, Male, Ovarian Neoplasms, Prostatic Neoplasms

NCT03992131 2024-01-16

A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)

Phase 1/2 Terminated

25 enrolled 11 charts

BreastGenitourinaryGynecologic

Carcinoma, Transitional Cell, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03840200 2023-10-30

A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.

Phase 1 Completed

51 enrolled 20 charts

BreastGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms

NCT04171700 2023-10-02

LODESTAR

Phase 2 Terminated

83 enrolled 16 charts

BreastGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinosarcoma, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Leiomyosarcoma, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04179396 2023-06-29

RAMP

Phase 1 Completed

8 enrolled 8 charts

Metastatic Castration Resistant Prostate Cancer

NCT02042378 2023-06-13

A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation

Phase 2 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT01891344 2023-06-12

ARIEL2

Phase 2 Completed

491 enrolled 19 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

NCT03824704 2023-06-12

A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)

Phase 2 Terminated

1 enrolled 7 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Carcinoma, Endometrioid

NCT01482715 2023-06-09

A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)

Phase 1/2 Completed

136 enrolled 30 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

NCT01968213 2023-06-09

ARIEL3

Phase 3 Completed

564 enrolled 18 charts 2 FDA

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02740712 2023-06-09

DDI

Phase 1 Completed

Neoplasms

NCT02855944 2023-06-09

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

Phase 3 Completed

349 enrolled 29 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

NCT02935634 2023-06-09

FRACTION-GC

Phase 2 Completed

190 enrolled 25 charts

Gastrointestinal

Advanced Gastric Cancer

NCT02952534 2023-06-09

TRITON2

Phase 2 Completed

277 enrolled 23 charts 3 FDA

Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related

NCT02986100 2023-06-09

AME

Phase 1 Completed

Other solid neoplasm

Solid Tumor

NCT03397394 2023-06-09

ATLAS

Phase 2 Terminated

97 enrolled 12 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT03499444 2023-06-09

A Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor

Phase 1 Completed

Other solid neoplasm

Advanced Solid Tumor

NCT03521037 2023-06-09

Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor

Phase 1 Completed

Neoplasms

NCT01009190 2023-06-08

A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens

Phase 1 Completed

Other solid neoplasm

Advanced Solid Tumors

NCT03954366 2023-06-08

Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives

Phase 1 Completed

Neoplasms

NCT03101280 2020-10-22

A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer

Phase 1 Completed

Genital Neoplasms, Female